Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Completed · Phase 1/Phase 2
Conditions studied: Melanoma
In brief
Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02D is to evaluate the safety and efficacy of investigational treatment arms in programmed cell-death 1 (PD-1) naïve or PD-1 exposed participants with melanoma brain metastasis (MBM) and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of amendment 2 (effective 01DEC2022) enrollment into the treatment arm of pembrolizumab and lenvatinib has been discontinued.
Key facts
- Study ID
- NCT04700072
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 56
- Starts
- 2021-05-03
- Expected to finish
- 2025-10-17
- Last updated by the study team
- 2025-10-28
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Has American Joint Committee on Cancer (AJCC) Stage IV, M1D melanoma
- Is neurologically asymptomatic from brain metastases and has not received systemic corticosteroid therapy in the 10 days prior to beginning study intervention
- If capable of producing sperm, male participants agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention is:
- Lenvatinib: 7 days
- Abstains from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent. OR
- Uses contraception unless confirmed to be azoospermic
- Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after the last dose of pembrolizumab or pembrolizumab/quavonlimab, or 30 days after the last dose of lenvatinib, whichever occurs last
- Has adequate organ function
- Female participants agree to abstain from breastfeeding during the study intervention period and for at least the time needed to eliminate study intervention after the last dose of study intervention. The length of time required for each study intervention is:
- MK-1308A: 120 days
- MK-3475: 120 days
- Lenvatinib: 30 days
You may not qualify if…
- Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 10 days before the first dose of study intervention
- Has current or history of known leptomeningeal involvement
- Has received stereotactic or highly conformal radiotherapy within 2 weeks before the start of dosing
- Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
- Has untreated or unresolved intracranial hemorrhage from central nervous system (CNS) metastasis
- Has an active infection requiring systemic therapy
- Has a known additional malignancy that is progressing or requires active treatment within the past 2 years
- Has ocular melanoma
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known history of immunodeficiency virus (HIV)
- Has known history of hepatitis B or known hepatitis C virus
- Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis
- Has received prior systemic anticancer therapy within 4 weeks prior to randomization/allocation
- Has a history of whole brain irradiation
- Has received prior radiotherapy within 2 weeks of first dose of study intervention
- Has had major surgery <3 weeks prior to first dose of study intervention
- Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention
- Has had an allogeneic tissue/solid organ transplant
Where it is running
- The Angeles Clinic and Research Institute ( Site 4009) — Los Angeles, California, United States
- UCLA Hematology & Oncology ( Site 4004) — Los Angeles, California, United States
- Providence Saint John's Health Center ( Site 4010) — Santa Monica, California, United States
- University of Colorado, Anschutz Cancer Pavilion ( Site 4012) — Aurora, Colorado, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 4022) — Baltimore, Maryland, United States
- NYU Clinical Cancer Center ( Site 4002) — New York, New York, United States
- Duke Cancer Institute ( Site 4005) — Durham, North Carolina, United States
- Martha Morehouse Tower ( Site 4020) — Columbus, Ohio, United States
- Inova Schar Cancer Institute ( Site 4011) — Fairfax, Virginia, United States
- Calvary Mater Newcastle ( Site 4404) — Waratah, New South Wales, Australia
- Melanoma Institute Australia ( Site 4402) — Wollstonecraft, New South Wales, Australia
- Hopital La Timone ( Site 4103) — Marseille, Bouches-du-Rhone, France
- CHU de Bordeaux- Hopital Saint Andre ( Site 4108) — Bordeaux, Gironde, France
- Institut Claudius Regaud ( Site 4105) — Toulouse, Haute-Garonne, France
- Centre Hospitalier Lyon Sud ( Site 4102) — Pierre-Bénite, Rhone, France
- A.P.H. Paris, Hopital Saint Louis ( Site 4107) — Paris, France
- Gustave Roussy ( Site 4101) — Villejuif, Île-de-France Region, France
- HaEmek Medical Center ( Site 4703) — Afula, Israel
- Rambam Health Care Campus-Oncology ( Site 4704) — Haifa, Israel
- Hadassah Ein Karem Jerusalem ( Site 4702) — Jerusalem, Israel
- Rabin Medical Center-Oncology ( Site 4705) — Petah Tikva, Israel
- Chaim Sheba Medical Center ( Site 4701) — Ramat Gan, Israel
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 4399) — Milan, Italy
- Istituto Europeo di Oncologia ( Site 4301) — Milan, Italy
- Istituto Nazionale Tumori Fondazione Pascale ( Site 4302) — Naples, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.